Collagenase clostridium histolyticum - BioSpecifics Technologies Corporation/Endo, Inc.
Alternative Names: AA-4500; AK-160; CCH; Clostridial collagenase; Collagenase clostridium histolyticum-aaes; Cordase; EN-3835; PF-5076985; Plaquase; Qwo; XIAFLEX; XiapexLatest Information Update: 27 Apr 2024
At a glance
- Originator BioSpecifics Technologies Corporation
- Developer Actelion Pharmaceuticals; Asahi Kasei; BioSpecifics Technologies Corporation; Endo International; Endo, Inc.; Swedish Orphan Biovitrum
- Class Antineoplastics; Collagenases; Skin disorder therapies; Urologics
- Mechanism of Action Collagenase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cellulite; Dupuytren's contracture; Peyronie's disease
- Phase III Fibroma
- Phase II Frozen shoulder; Lipoma
- No development reported Breast disorders; Metabolic disorders; Uterine leiomyoma
- Discontinued Hypertrophic scars; Keloids; Tendon injuries
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 21 Mar 2024 Endo Pharmaceuticals completes a phase III trial in Fibroma in USA (Intralesional) (NCT05254457)
- 02 Feb 2024 Endo Pharmaceuticals initiates phase III STRIDE trial for Fibroma (Intralesional) in USA (NCT06151197)